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Abstract
This retrospective study aims to determine whether
there is a difference in the additional consumption of
alcohol between addicts treated with methadone or dihy-
drocodeine (DHC) and untreated addicts injecting heroin.
1,685 patients admitted for opioid withdrawal between
1991 and 1997 were reviewed. Cross-reference tables
and multiple logistic regression analyses were carried
out. 28% of patients take more than 40 g of alcohol daily
(on average 176 g). We found that patients who are
treated with methadone or DHC drink alcohol significant-
ly more often daily than the heroin-dependent patients
(p ! 0.01). Using multiple regression analyses, the results
were confirmed. Additionally, we found that co-abuse of
alcohol was predicted by male gender, longer duration
of drug use, additional daily consumption of tetrahydro-
cannabinol and daily consumption of benzodiazepines.
Alcohol consumption by opioid-addicted patients
treated with methadone or DHC presents a serious medi-
cal problem. Co-abuse of alcohol will receive more atten-
tion.
Copyright © 2003 S. Karger AG, Basel
Introduction
Consumption of other psychotropic substances during
substitution treatment of opioid addicts with methadone
and dihydrocodeine (DHC) may have a substantial im-
pact on morbidity, mortality and clinical course. While
consumption of illegal drugs is usually reduced during
substitution treatment, additional consumption of legal
psychotropic substances, especially of alcohol, has not
been examined in such detail. Chronic alcohol consump-
tion leads to a variety of somatic effects and diseases.
Therefore, where a high prevalence of regular or severe
alcohol consumption exists among patients in substitu-
tion programs, the advantages and risks should be careful-
ly weighed up. Further, to the consumption of respirant-
depressive opioids, additional complications and dangers
are involved when taking other psychotropic substances
with respiration-depressive effects, such as alcohol, ben-
zodiazepines or barbiturates. 62–72% of the patients, who
had been treated for overdosing, had consumed various
substances [1, 2], of which 23–35% comprised alcohol. In
cases of fatal overdosing, abuse with multiple substances
was reported in 71–92% of patients [3–7]. In 41–51% of
these deaths, alcohol was identified. In addition to the
acute risk of an overdose from combined consumption of
a number of psychotropic substances, the consumption of
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alcohol, in contrast to opioids, leads to chronic permanent
damage and disease concerning almost all aspects of med-
icine [8–11].
On the one hand, a number of studies have ascertained
that the supplementary consumption of illegal drugs such
as heroin and cocaine may be reduced by methadone
maintenance treatment programs [12–15] and codeine
maintenance programs [16]. On the other hand, it has
often been reported that about 30% of the patients in
methadone maintenance treatment programs have an
alcohol problem or are even alcoholics [17–19]. It is not
clear, however, whether the patients already had alcohol
problems before their entry into the methadone mainte-
nance treatment. The North Rhine Westphalia study on
the efficacy of outpatient medical rehabilitation with
methadone maintenance indicated that over time the
number of patients being abstinent of alcohol increased
during treatment [20].
In Germany, the critical dose is often stated as 60 g for
men and 40 g for women [21]. More than 8,000 deaths of
people aged 15–29 years in Europe in 1999 were attribut-
able to alcohol [22].
In addition to the risk of overdosing, alcoholism for
example leads to an increased risk of long-term secondary
physical sicknesses [8, 9]. With regard to narcotics fatali-
ties, toxicological data from southern Bavaria – the same
area as in our study – indicate that alcohol is a frequent
covariant in drug-related deaths and in patients treated
with codeine (27% each) and that it is less frequent in
methadone patients (16%) [23].
Those studies concerned with supplementary con-
sumption within methadone and codeine maintenance
treatment programs have mainly focused on the supple-
mentary consumption of illegal drugs. We further consid-
er that in Germany, and especially Bavaria, where alcohol
is everywhere easily available and where alcohol con-
sumption is well established (e.g. the ‘Oktoberfest’), her-
oin addicts consider alcohol consumption analogous to a
‘normal’ individual’s regular consumption of alcohol, and
more so when heroin becomes more difficult to obtain.
We thus present our hypothesis that those patients treated
with methadone or DHC drink less alcohol than the
untreated patients injecting illegal heroin.
Subjects and Methods
Sample
All drug-addicted patients voluntarily admitted to inpatient de-
toxification treatment between April 1991 and December 1996, in
whom, according to ICD-10 criteria, an opioid or multiple-substance
addiction had been diagnosed, were included in the study. Of all
patients enrolled in the treatment program between April 1991 and
December 1996, those subjects coming for a second or third detoxifi-
cation visit within this time period had to be excluded, except for the
first visit, otherwise the assumption of independent observations
would have been violated. Patients could come in of their own voli-
tion, and previous contact with a counsellor or physician was not
necessary. The treatment strategy called ‘qualified detoxification’ has
been described elsewhere [24].
Measures
On the day of admission, the daily intake of psychotropic sub-
stances over the preceding 6 months was established. The patients
were questioned individually regarding their intake of opioids, espe-
cially heroin, codeine/DHC and methadone (D, L-methadone, le-
vomethadone), and of other psychotropic substances such as nico-
tine, benzodiazepines, barbiturates, cocaine, cannabis, amphet-
amines/amphetamine derivatives and alcohol. The alcohol intake
was noted in grams of alcohol per day. 500 ml beer was calculated as
20 g alcohol, 500 ml cognac (40%) or vodka (40%) as 160 g alcohol
[21]. The declarations were verified by an immunoassay urine test
(Triage®) and a KIMS test (kinetic interaction of microparticles in a
solution).
The patients were divided into 3 groups according to the pre-
ferred opioid of each individual. Those who daily received metha-
done or levomethadone (summarized as methadone) were included
in group 1, those who took codeine or DHC daily (summarized as
DHC) in group 2 and those daily consuming heroin in group 3. If
primarily two opioids were taken daily, then the priority sequence of
heroin before methadone before DHC was decisive. If none of the
opioids were taken daily, but rather several of them alternatively,
then these patients were not introduced into any of the 3 groups.
Data concerning the daily intake of other psychotropic substances
were collected for each group, as well as the gender of the patient,
duration of addiction, age at first opioid use, age, marital status, his-
tory of imprisonment, history of suicide attempts and employment.
Alcohol was separated and selected as a dependent variable (co-abuse
of alcohol). Co-abuse of alcohol was defined as consumption of more
than 40 g alcohol per day. The 40-gram value was chosen since it is
the stated critical dose of alcohol per day in most other published
reports [21, 22, 25, 26].
Statistics
After cross-tabulation and bivariate analysis, a logistic regression
model was established. Bivariate analyses were performed for the
variable of interest and all further potentially relevant variables.
Since preliminary analysis indicated nonlinear associations involv-
ing type of opioid dependency, age, duration of drug use, age at first
opioid use, marital status and history of imprisonment, these vari-
ables were transformed from ordinal to categorical variables. Results
are summarized by reporting a ‘full model’ that includes all investi-
gated variables regardless of their statistical significance. Tests for
interactions were used as a check on the uniformity assumption
under which multiple regression estimates are derived.
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Results
During the observation period from April 1991 to
December 1996, 1,656 patients were voluntarily admitted
to stationary qualified withdrawal treatment, 36% wom-
en and 64% men. 537 of these were patients readmitted
within the given time frame. Of these patients only the
first admission was included in the study in order not to
violate the assumption of independent observations. 49
patients were not included since they had daily consumed
several different opioids. 137 patients, 36% women and
64% men, who daily received methadone, were included
in group 1. 658 patients, 34% women and 66% men, due
to their daily intake of codeine/DHC were placed into
group 2. 275 patients, 39% women and 61% men, daily
consuming heroin formed group 3. The average age was
30.7 years in group 1, 28.9 years in group 2 and 28.3 years
in group 3. The average duration of addiction to opioids
was substantiated as 10.5 years in group 1, 8.9 years in
group 2 and 8.2 years in group 3.
301 patients consumed more than 40 g alcohol per day.
These were evaluated as positive for the dependent vari-
able ‘co-abuse of alcohol’. On average, alcohol consump-
tion was 176 g/day (table 1).
Contrary to our hypothesis, the bivariate analysis indi-
cated that patients who are in a methadone or DHC main-
tenance treatment program daily drink alcohol signifi-
cantly more often than the heroin-dependent patients (p !
0.01). Fewer patients who were treated with DHC
(31.3%) drink alcohol than patients who were treated with
methadone (36.5%). Table 2 presents bivariate analyses
on the key variable and possible confounding variables
predicting co-abuse of alcohol. As shown, co-abuse of
alcohol was predicted by male gender, older age, longer
duration of drug use, additional daily consumption of
tetrahydrocannabinol (THC), daily consumption of bar-
biturates and daily consumption of benzodiazepines.
Table 3 shows the results of a multiple logistic regres-
sion analysis. The key finding that patients consuming
heroin drink less alcohol than patients who were treated
with DHC or methadone persists even when all investi-
gated variables regardless of their statistical significance
were included in the model. Age and daily consumption
of barbiturates turned out not to be a significant predictor
of co-abuse of alcohol. None of the other previously
entered significant variables like gender (odds ratio, OR,
0.61, 95% confidence interval, CI, 0.44–0.84, p ! 0.01),
duration of drug use (OR 0.19, 95% CI 0.05–0.74, p !
0.05), daily consumption of benzodiazepines (OR 0.52,
95% CI 0.38–0.71, p ! 0.001) and daily consumption of
Table 1. Consumption of alcohol by opioid patients consuming
more than 40 g of alcohol per day (defining ‘co-abuse of alcohol’)
Quantity of alcohol
g/day






More than 240 23.6
Total 100
THC (OR 0.67, 95% CI 0.47–0.95, p ! 0.05) became
insignificant, even though our variable of interest ‘type of
opioid dependency’ remained only marginally significant
(OR 2.38, 95% CI 1.42–4.00, p ! 0.001; table 3).
Discussion
The aim of this study was to investigate the association
between the consumption of alcohol and the daily pre-
ferred opioid (methadone, DHC or heroin). The results
indicate that patients consuming heroin drink less alcohol
on a regular basis. In comparison to the patients who con-
sume DHC, patients in a methadone maintenance pro-
gram drink alcohol more often (36.5% of the methadone
patients vs. 31.3% of the DHC patients). The hypothesis
had therefore to be rejected. One explanation might be
due to the effect of the substance, i.e. that heroin is the one
substance with which the desired effect according to the
addicts may best be attained. Other opioids such as meth-
adone and DHC do not completely produce the desired
effect so that other additional substances, e.g. alcohol, are
consumed. In published reports, problematic alcohol con-
sumption by opiate users is given as varying between 12%
[27], 32% [18, 28] and 42% [27]. In this spectrum, the
individual subgroups of our study are found, with 16%
problem drinkers in the heroin group, 31.3% in the
codeine group and 36.5% in the methadone group. It is
becoming increasingly possible in Europe to use various
opioids as substitutes. This is understandable when one
considers the high mortality rate of drug addicts, which,
in a meta-analysis, was found to be more than 13 times
greater than in the average populations’ equivalent age
group [29]. Researchers and practitioners are therefore
required to re-evaluate indication positions and to anno-
tate advantages and disadvantages of each substance. An
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Table 2. Cross-tabulation and bivariate
analyses for the primary variables of
interest and secondary potentially relevant
variables
Variable Co-abuse of alcohol (more than 40 g alcohol per day)
n % OR 95% CI p
Type of opioid dependency 0.0000
Methadone 137 36.5 3.02 1.88–4.85 0.0000
DHC 658 31.3 2.39 1.67–3.44 0.0000
Heroin 275 16.0 1
Sex
Female 377 21.2 0.58 0.43–0.78 0.0003
Male 693 31.7 1
Age 0.0081
!23 years 217 21.7 0.58 0.37–0.91 0.0169
24–28 years 340 24.7 0.69 0.46–1.02 0.0639
29–34 years 324 33.0 1.04 0.70–1.52 0.0851
134 years 186 32.3 1
Duration of opioid use 0.0000
!1 year 79 06.3 0.14 0.64–1.96 0.0001
2–5 years 392 24.0 0.66 0.62–1.28 0.0316
6–10 years 251 30.3 0.90 0.66–1.47 0.6277
11–15 years 160 40.0 1.39 0.68–1.65 0.1438
115 years 188 32.4 1
Daily consumption of THC
No 873 26.3 0.65 0.47–0.90 0.0100
Yes 197 35.5 1
Daily consumption of barbiturates
No 995 27.2 0.59 0.37–0.97 0.0352
Yes 75 38.7 1
Daily consumption of benzodiazepines
No 597 20.9 0.45 0.34–0.59 0.0000
Yes 473 37.0 1
The variables ‘age at first opioid use’, ‘marital status’, ‘history of imprisonment’, ‘history
of emergency treatment’, ‘history of suicide attempts’, ‘employment’ and ‘daily consumption
of cocaine’ were not significant.
OR = Odds ratio; 95% CI = 95% confidence interval; THC = tetrahydrocannabinol.
important target criterion should be the parallel consump-
tion of further psychotropic substances, especially alco-
hol. It is known that alcohol has a toxic effect on all
organic systems and that therefore chronic consumption
of alcohol causes many severe illnesses. If the patients
now begin to drink alcohol during the methadone or DHC
substitution treatment, then a serious responsibility falls
upon the physicians to recognize, and where necessary to
prevent, the injurious alcohol consumption being caused
perhaps partly by the substitution treatment itself. Fur-
ther studies had to be conducted to prove the association
between methadone or other substitutes and drinking
alcohol, and to investigate how long patients can be
treated with methadone before the risk of excessive alco-
hol consumption increases significantly. A previous study
showed that 29% of the patients initially began to drink
during the course of methadone maintenance treatment
programs and that they are younger in comparison to non-
opioid-addicted alcoholics [30]. Numerous studies con-
tinue to substantiate that patients during substitution
treatment with methadone consume fewer illegal drugs,
that the risk of HIV infection is reduced and that drug-
related crime rates fall [20, 31–33]. DHC, which is fre-
quently prescribed in Germany, appears to improve the
addicts’ situation just as well as methadone [16]. In all
these studies, the illicit drug co-abuse but not alcohol was
a target criterion. In a new study, it was reported that only
one third of the patients in methadone maintenance treat-
ment abstained from alcohol at the intake and follow-up
[34]. It is known that with a lower dosage of methadone,
co-abuse is higher [35]. Apparently, patients who discover
they are hepatitis C positive, reduce their alcohol con-
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Table 3. Multiple logistic regression analyses: full model for the pri-
mary variables of interest and secondary potentially relevant vari-
ables
Variable Co-abuse of alcohol
(more than 40 g alcohol per day)
OR 95% CI p
Type of opioid dependency 0.0038
Methadone 2.38 1.42–4.00 0.0010
DHC 1.67 1.12–2.49 0.0124
Heroin 1
Sex
Female 0.61 0.44–0.84 0.0025
Male 1
Age 0.7734
!23 years 0.71 0.27–1.82 0.4715
24–28 years 0.72 0.35–1.48 0.3711
29–34 years 0.92 0.55–1.55 0.7521
134 years 1
Duration of opioid use 0.0220
!1 year 0.19 0.05–0.74 0.0167
2–5 years 0.81 0.35–1.88 0.6253
6–10 years 0.98 0.49–1.96 0.9484
11–15 years 1.36 0.76–2.46 0.3022
115 years 1
Daily consumption of benzodiazepines
No 0.52 0.38–0.71 0.0000
Yes 1
Daily consumption of barbiturates
No 0.82 0.48–1.41 0.4773
Yes 1
Daily consumption of THC
No 0.67 0.47–0.95 0.0252
Yes 1
The variables ‘marital status’, ‘history of imprisonment’, history
of emergency treatment’, ‘history of suicide attempts’, ‘employment’,
‘age at first opioid use’ and ‘daily consumption of cocaine’ remained
insignificant.
OR = Odds ratio; 95% CI= 95% confidence interval.
sumption considerably [28]. In principle it should be tak-
en into consideration that in Germany alcohol is cultur-
ally accepted. Possibly the results would be somewhat dif-
ferent in a more abstinence-oriented culture.
Independently of the preferred daily opioid the follow-
ing variables were associated with co-abuse of alcohol:
(1) in the total population, males more often have an alco-
hol problem than females [36–38] – so it was not surpris-
ing that male opioid addicts more often had drunk alcohol
daily than female opioid addicts; (2) that older patients,
consuming drugs over a longer period, drink more alcohol
seems realistic since the drug alone no longer appears to
have the desired effect; (3) this would be an analogous
explanation of the significantly higher benzodiazepine
and cannabis consumption. Barbiturates are consumed
(in total) in such small quantities that its use is difficult to
assess with certainty. The subgroup of cocaine users is
also so small that an assessment here appears to be of little
practical value.
The multiple logistic regression analysis result proves
that patients who have been treated with methadone or
have taken DHC drink quite significantly more than
patients who have injected heroin intravenously. To our
knowledge this has not yet been described thus in any oth-
er literature. It is nevertheless necessary to consider that
this concerns a retrospective study. Being male, addition-
al consumption of benzodiazepines and THC was also
confirmed as independent predictor for alcohol co-abuse.
Increased age was not asserted as an independent predic-
tor, but duration of drug use was. This may be explained
by the fact that increased age implies a longer period of
drug use, since drug addicts in this study on average first
began injecting heroin at 20 years of age. In the first year
of opioid consumption, it appeared that the opioid itself
achieved the desired effect. Not quite every sixteenth
patient drinks alcohol additionally. Already from the sec-
ond year onward every fourth patient drinks alcohol dai-
ly. From the sixth to the tenth year, the proportion was
30%, from the eleventh to the fifteenth year 40%. The
effect of the opioid itself no longer appears to be suffi-
cient. With an opioid consumption of more than 15 years,
slightly fewer patients drank alcohol daily (32.4%). This is
comparable to a British study in which a 32% harmful
daily alcohol consumption has been diagnosed, where the
average duration of opioid dependence was 17 years and
the average age was 39 [28].
The results of this study suggest that co-abuse of alco-
hol should receive more attention in further studies of the
effectiveness of substitution treatment programs with var-
ious substitution drugs. Particularly, a comparison be-
tween heroin and methadone should prove very interest-
ing. More longitudinal studies are still needed.
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